Skip to main content
Premium Trial:

Request an Annual Quote

Richard Wender, Lewis Bender, Kathy Kopnisky, Laura Lyman Rodriguez, Eric Kaldjian, Meeta Patnaik

Epigenomics has named Richard Wender to the company’s medical advisory board for colorectal cancer screening.

Interleukin Genetics has appointed Lewis Bender to the post of CEO. Bender has been involved in biotechnology for over 15 years as a senior executive, including holding the post of senior VP of business development and VP of manufacturing and CTO at Emisphere Technologies.

The National Human Genome Research Institute brought in Kathy Kopnisky as chief of staff in the Immediate Office of the Director. Acting Chief Laura Lyman Rodriguez will return to take on policy matters as senior advisor to the director for research policy.
Kopnisky arrives at NHGRI from the National Institute of Mental Health, where she most recently was chief of HIV Therapeutics/Clinical Trials and Psychiatric Programs. Rodriguez has been with NHGRI since 2002 as a health policy analyst and as special advisor to the director.

Transgenomic has appointed Eric Kaldjian to the job of chief scientific officer. Kaldjian formerly was executive director of medical sciences at Gene Logic, and he was an oncology and experimental medicine researcher at Pfizer Global Research and Development. In his new office, Kaldjian will lead Transgenomic’s R&D and biomarker research.

Clinical Data has named Meeta Patnaik to be senior VP of predictive diagnostics and Marcia Lewis to the post of VP of biomarker development.
Patnaik formerly was chief medical officer at Lipomics Technologies and was a founder of Pathway Diagnostics, where she also was senior VP and chief science and technology officer. Lewis recently was senior director of oncology at Celera and was director of genomics and bioinformatics, among other titles, at Bayer Diagnostics.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.